Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 1/20 | 0.42 |
| ▸ | F9 | P00740 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923453 | 0.89 | MAPK1 (0.63) | MAPK1SIRT2NR1H4ALDH1A1RAB9A | |
| SCHEMBL5923256 | 0.83 | MAPK1 (0.56) | MAPK1SIRT2NR1H4RAB9ANPC1 | |
| SCHEMBL5923055 | 0.82 | RAB9A (0.49) | MAPK1SIRT2ALDH1A1RAB9ANPC1 | |
| SCHEMBL5923220 | 0.81 | MAPK1 (0.54) | MAPK1SIRT2NR1H4ALDH1A1RAB9A | |
| SCHEMBL5923599 | 0.80 | ALDH1A1 (0.49) | MAPK1SIRT2ALDH1A1RAB9ANPC1 | |
| SCHEMBL5923526 | 0.79 | MAPK1 (0.57) | MAPK1SIRT2NR1H4RAB9ANPC1 | |
| SCHEMBL6517622 | 0.78 | MAPK1 (0.80) | MAPK1SIRT2ALDH1A1RAB9A | |
| SCHEMBL5923121 | 0.78 | MAPK1 (0.48) | MAPK1SIRT2F9 | |
| SCHEMBL14861785 | 0.77 | GAA (0.46) | MAPK1ALDH1A1RAB9ANPC1 | |
| SCHEMBL5923163 | 0.76 | RAB9A (0.52) | SIRT2ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| WO-2005095345-A2 | HETEROARYL GUANIDINES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | MAPK1 2055/4885SIRT2 1645/4885NR1H4 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.